CP60 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Moderate LeverageA low debt-to-equity ratio and a large equity base provide durable financial flexibility to fund R&D, capex, M&A or absorb shocks. This balance-sheet strength supports multi-year capital allocation and lowers refinancing risk, improving resilience through cycles and strategic initiatives.
Market Leadership In Contact LensesLeading market share in contact lenses creates scale advantages in manufacturing, distribution and branding, supporting durable revenue streams and pricing power. Strong position aids product launches, fosters channel relationships, and sustains recurring demand for lens consumables over years.
Reaffirmed Multi-year Free Cash Flow TargetsManagement's multi-year free-cash-flow targets indicate structural focus on converting earnings to cash. Sustained FCF improves funding for innovation, dividends/buybacks, and potential strategic transactions, and signals management confidence in operational cash generation beyond one-time items.
Bears Say
Deteriorating Profitability And MarginsA marked decline in net margin and weaker free-cash-flow conversion reduces earnings quality and the firm's ability to self-fund growth. If margin pressure persists from costs, FX or product mix shifts, it can meaningfully constrain reinvestment, returns on capital, and long-term shareholder value.
Significant Litigation-related Cash ObligationsMaterial litigation payouts are concentrated in fiscal 2026 and reduce available cash and GAAP earnings. Such obligations create execution and capital-allocation uncertainty, may limit buybacks/acquisitions, and raise the risk that future cash targets need adjustment if additional liabilities emerge.
Asia Pacific Weakness And Product RationalizationSustained APAC softness and legacy product rationalization hit a key geographic market, reducing growth optionality. Persistent weakness in Japan/China can lower global revenue growth, underutilize manufacturing scale, and slow adoption of newer products in large addressable markets.
Cooper Co News
CP60 FAQ
What was Cooper Co’s price range in the past 12 months?
Currently, no data Available
What is Cooper Co’s market cap?
Cooper Co’s market cap is CHF11.73B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Sep 09, 2026 which is in 28 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Jun 04, 2026. The company reported CHF0.98 earnings per share for the quarter, beating the consensus estimate of CHF0.894 by CHF0.086.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co does not currently pay dividends.
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 0.91.
How many shares outstanding does Cooper Co have?
Currently, no data Available
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of CHF0.98 in its last earnings report, beating expectations of CHF0.894. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in CH:CP60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF62.85 (― Upside)
CHF62.85 (― Upside)
Blogger Sentiment
Bullish
CH:CP60 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
CP60 Company Deck
CP60 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all CH:CP60 earnings summariesCP60 Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
